Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

  • End date
    Mar 20, 2024
  • participants needed
  • sponsor
Updated on 4 October 2022


The proposed study is designed to examine the effects of AZD0171 and durvalumab in combination with standard-of-care chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).


This is a Phase II, open-label, single arm, multicentre study to assess the safety, preliminary antitumour activity, immunogenicity, pharmacodynamics (PD), and pharmacokinetics (PK) of AZD0171 in combination with durvalumab and standard-of-care chemotherapy (gemcitabine and nab-paclitaxel) in participants with first line (1L) metastatic pancreatic ductal adenocarcinoma (mPDAC).

All participants will be treated until progressive disease or unacceptable toxicity or withdrawal of consent or another discontinuation criterion is met.

Condition Locally Advanced or Metastatic Solid Tumours
Treatment Gemcitabine, Nab-paclitaxel, durvalumab, AZD0171
Clinical Study IdentifierNCT04999969
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Eastern Cooperative Oncology Group performance status of 0 or 1 at screening/enrolment
Must have a Gustave Roussy Immune Score of 0 or 1
Participants diagnosed with histologically confirmed pancreatic adenocarcinoma
Participants must have at least 1 measurable lesion to be called a target lesion according to RECIST v1.1
All participants must consent to providing sufficient archival specimen taken during metastatic stage or fresh tumour specimens for tumoural CD8+ T cell testing for enrolment
Presence of tumoural CD8+ T cells based on a predetermined benchmarked PDAC external sample
Normal organ and bone marrow function measured within 28 days prior to first dose of study intervention
Body weight ≥ 35 kg

Exclusion Criteria

Symptomatic central nervous system metastasis or any history of leptomeningeal disease or cord compression
A participant with an already known sensitising mutation or tumour characteristic for pancreatic cancer for which there is a preferred local standard-of-care treatment
History of thromboembolic event within the past 3 months prior to the scheduled first dose of study intervention
Any unresolved toxicities ≥ Grade 2 per Common Terminology Criteria for Adverse Events v5.0 from prior therapy (excluding vitiligo, alopecia, controlled diabetes)
History of solid organ transplantation
History of active primary immunodeficiency
Ongoing or an active infection, including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus. For Coronavirus disease 2019 (COVID-19) infections, a negative polymerase chain reaction test is required
Uncontrolled intercurrent illness
Participants with prior history of myocardial infarction, transient ischemic attack, coronary bypass, or stroke within the past 3 months prior to the first dose of study intervention
Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms calculated from 3 electrocardiograms
Active or prior documented autoimmune or inflammatory disorders
History of another primary malignancy
Receipt of any conventional or investigational anticancer therapy prior to the scheduled first dose of study intervention
Prior receipt of any immune-mediated therapy
Use of immunosuppressive medication within 14 days prior to the first dose of study intervention
Receipt of live, attenuated vaccine within 28 days prior to the first dose of study intervention (Participants can receive non-live COVID-19 vaccines, at the discretion of the Investigator)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note